CODOMAX INC.

Worcester, MA · Biotech · Private

Codon engineering platform for optimizing gene sequences to increase recombinant protein yield in cell-based manufacturing

codomax.com →
Grants
$1.0M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Exploiting translation elongation for improved biologics manufacturing$324,999
Federal grantDepartment of Health and Human Services · Phase I · Optimizing Antibody Production in CHO Cells Using Epi-MAX Technology to Increase Heavy and Light Chain Expression$350,000
Federal grantDepartment of Health and Human Services · Phase I · Designer Pichia Strains That Enable Difficult-To-Express Biologics Production by Addressing Limitations in Secretory Protein Expression$350,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1258GPN THERAPEUTICS, INC.——
1259AYTU BIOSCIENCE, INC—$26M
1260NANODESK, LLC——
1261CODOMAX INC.——
1262Young Biopharma, LLC——
1263Proteovant Therapeutics——
1264Pelthos Therapeutics Inc.—$69M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.